Can Antimalarial Phytochemicals be a Possible Cure for COVID-19? Molecular Docking Studies of Some Phytochemicals to SARS-CoV-2 3C-like Protease

Infect Disord Drug Targets. 2022;22(1):e290721195143. doi: 10.2174/1871526521666210729164054.

Abstract

Objective: To evaluate the efficacy of reported anti-malarial phytochemicals as lead compounds for possible drug development against COVID-19.

Methods: An in silico approach was used in this study to determine through molecular docking the binding affinities and site of binding of these phytochemicals to the 3C-like protease of COVID-19 which is considered as the main protease of the virus.

Results: A number of anti-malarial phytochemicals like apigenin-7-O-glucoside, decurvisine, luteolin- 7-O-glucoside, sargabolide J, and shizukaols A, B, F, and G showed predicted high binding energies with ΔG values of -8.0 kcal/mol or higher. Shizukaols F and B demonstrated the best binding energies of -9.5 and -9.8, respectively. The acridone alkaloid 5-hydroxynoracronycine also gave a predicted high binding energy of -7.9 kcal/mol.

Conclusion: This is for the first time that decursivine and several shizukaols were reported as potential anti-viral agents. These compounds merit further studies to determine whether they can be effective drug candidates against COVID-19.

Keywords: COVID-19; SARS-CoV-2 3C-like protease; anti-malaria; drug development; phytochemicals; shizukaols.

MeSH terms

  • Antimalarials* / pharmacology
  • Antimalarials* / therapeutic use
  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • COVID-19 Drug Treatment*
  • Coronavirus 3C Proteases
  • Glucosides
  • Humans
  • Molecular Docking Simulation
  • Peptide Hydrolases
  • Phytochemicals / pharmacology
  • Phytochemicals / therapeutic use
  • SARS-CoV-2

Substances

  • Antimalarials
  • Antiviral Agents
  • Glucosides
  • Phytochemicals
  • Peptide Hydrolases
  • Coronavirus 3C Proteases